PMC:7281546 / 26001-26864 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T158","span":{"begin":174,"end":185},"obj":"Body_part"},{"id":"T159","span":{"begin":310,"end":314},"obj":"Body_part"}],"attributes":[{"id":"A158","pred":"fma_id","subj":"T158","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A159","pred":"fma_id","subj":"T159","obj":"http://purl.org/sig/ont/fma/fma74402"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T233","span":{"begin":150,"end":156},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T234","span":{"begin":286,"end":295},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T235","span":{"begin":310,"end":314},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T236","span":{"begin":513,"end":516},"obj":"http://purl.obolibrary.org/obo/CLO_0001003"},{"id":"T237","span":{"begin":595,"end":605},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T238","span":{"begin":651,"end":652},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T239","span":{"begin":664,"end":665},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T240","span":{"begin":805,"end":806},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T185","span":{"begin":166,"end":169},"obj":"Chemical"},{"id":"T186","span":{"begin":190,"end":192},"obj":"Chemical"},{"id":"T188","span":{"begin":199,"end":202},"obj":"Chemical"},{"id":"T189","span":{"begin":207,"end":209},"obj":"Chemical"},{"id":"T191","span":{"begin":216,"end":219},"obj":"Chemical"},{"id":"T192","span":{"begin":224,"end":226},"obj":"Chemical"},{"id":"T194","span":{"begin":237,"end":240},"obj":"Chemical"},{"id":"T195","span":{"begin":647,"end":649},"obj":"Chemical"},{"id":"T198","span":{"begin":687,"end":690},"obj":"Chemical"},{"id":"T199","span":{"begin":780,"end":783},"obj":"Chemical"},{"id":"T200","span":{"begin":801,"end":803},"obj":"Chemical"},{"id":"T203","span":{"begin":842,"end":845},"obj":"Chemical"}],"attributes":[{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A187","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A188","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A190","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A191","pred":"chebi_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A193","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_141424"},{"id":"A196","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_25573"},{"id":"A197","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_1224"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A199","pred":"chebi_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A200","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_141424"},{"id":"A201","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_25573"},{"id":"A202","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_1224"},{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T151","span":{"begin":108,"end":131},"obj":"http://purl.obolibrary.org/obo/GO_0045087"},{"id":"T152","span":{"begin":286,"end":304},"obj":"http://purl.obolibrary.org/obo/GO_0007165"},{"id":"T153","span":{"begin":286,"end":295},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T154","span":{"begin":310,"end":325},"obj":"http://purl.obolibrary.org/obo/GO_0010467"},{"id":"T155","span":{"begin":550,"end":573},"obj":"http://purl.obolibrary.org/obo/GO_0000981"},{"id":"T156","span":{"begin":550,"end":565},"obj":"http://purl.obolibrary.org/obo/GO_0006351"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T183","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T184","span":{"begin":133,"end":258},"obj":"Sentence"},{"id":"T185","span":{"begin":259,"end":365},"obj":"Sentence"},{"id":"T186","span":{"begin":366,"end":518},"obj":"Sentence"},{"id":"T187","span":{"begin":519,"end":763},"obj":"Sentence"},{"id":"T188","span":{"begin":764,"end":863},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"2_test","denotations":[{"id":"32403318-24751921-82827383","span":{"begin":245,"end":248},"obj":"24751921"},{"id":"32403318-12483210-82827384","span":{"begin":249,"end":252},"obj":"12483210"},{"id":"32403318-23291588-82827385","span":{"begin":253,"end":256},"obj":"23291588"},{"id":"32403318-19686699-82827386","span":{"begin":513,"end":516},"obj":"19686699"},{"id":"32403318-19570999-82827387","span":{"begin":858,"end":861},"obj":"19570999"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"770","span":{"begin":166,"end":172},"obj":"Gene"},{"id":"771","span":{"begin":174,"end":188},"obj":"Gene"},{"id":"772","span":{"begin":190,"end":195},"obj":"Gene"},{"id":"773","span":{"begin":199,"end":205},"obj":"Gene"},{"id":"774","span":{"begin":207,"end":213},"obj":"Gene"},{"id":"775","span":{"begin":216,"end":222},"obj":"Gene"},{"id":"776","span":{"begin":224,"end":230},"obj":"Gene"},{"id":"777","span":{"begin":237,"end":243},"obj":"Gene"},{"id":"778","span":{"begin":647,"end":652},"obj":"Gene"},{"id":"779","span":{"begin":780,"end":786},"obj":"Gene"},{"id":"780","span":{"begin":801,"end":806},"obj":"Gene"},{"id":"781","span":{"begin":842,"end":847},"obj":"Gene"},{"id":"782","span":{"begin":687,"end":690},"obj":"Gene"},{"id":"783","span":{"begin":150,"end":156},"obj":"Species"}],"attributes":[{"id":"A770","pred":"tao:has_database_id","subj":"770","obj":"Gene:282618"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"Gene:282618"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"Gene:282618"},{"id":"A773","pred":"tao:has_database_id","subj":"773","obj":"Gene:282616"},{"id":"A774","pred":"tao:has_database_id","subj":"774","obj":"Gene:282616"},{"id":"A775","pred":"tao:has_database_id","subj":"775","obj":"Gene:282617"},{"id":"A776","pred":"tao:has_database_id","subj":"776","obj":"Gene:282617"},{"id":"A777","pred":"tao:has_database_id","subj":"777","obj":"Gene:282617"},{"id":"A778","pred":"tao:has_database_id","subj":"778","obj":"Gene:4790"},{"id":"A779","pred":"tao:has_database_id","subj":"779","obj":"Gene:282618"},{"id":"A780","pred":"tao:has_database_id","subj":"780","obj":"Gene:4790"},{"id":"A781","pred":"tao:has_database_id","subj":"781","obj":"Gene:3439"},{"id":"A782","pred":"tao:has_database_id","subj":"782","obj":"Gene:3439"},{"id":"A783","pred":"tao:has_database_id","subj":"783","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Type III IFNs have been explored in recent years, to unravel the underlying mechanisms that manipulate host innate immune responses. Type III IFNs in humans contains IFN-λ1 (interleukin 29 [IL-29]), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and IFN-λ4 [160,161,162]. Their expression profiles, signaling pathways, and gene expression programs resemble those of type I IFNs. The production of type I and III IFNs are both initiated through the recognition of PAMPs or damage associated molecular patterns (DAMPs) by PRRs [163]. Despite the fact that the same transcriptional factors are required for the activation of promoters of type I and III IFNs, the NF-κB pathway is a pivotal regulator in IFN-λ production, whereas the IRFs pathway dominates type I IFNs expression. The promoter of IFN-λ1 includes more NF-κB binding sites compared with in the IFN-β promoter [164]."}